• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by LivaNova PLC

    4/29/26 8:31:49 AM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $LIVN alert in real time by email
    DEFA14A 1 tm261392d4_defa14a.htm DEFA14A

     

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A

     

    Proxy Statement Pursuant to Section 14(a) of

    the Securities Exchange Act of 1934 (Amendment No.         )

     

    Filed by the Registrant x

     

    Filed by a Party other than the Registrant ¨

     

    Check the appropriate box:

     

    ¨Preliminary Proxy Statement

     

    ¨Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ¨Definitive Proxy Statement

     

    xDefinitive Additional Materials

     

    ¨Soliciting Material under §240.14a-12

     

    LivaNova PLC

    (Name of Registrant as Specified In Its Charter)

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check the appropriate box):

     

    xNo fee required.

     

    ¨Fee paid previously with preliminary materials

     

    ¨Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     

     

     

     

     

    GRAPHIC

    Step 1: Go to www.envisionreports.com/LIVN. Step 2: Click on Cast Your Vote or Request Materials. Step 3: Follow the instructions on the screen to log in. www.envisionreports.com/LIVN Online Go to www.envisionreports.com/LIVN or scan the QR code — login details are located in the shaded bar below. 2026 Annual General Meeting Notice 049VYH Important Notice Regarding the Availability of Proxy Materials for the 2026 Annual General Meeting to be held on June 10, 2026 Under Securities and Exchange Commission rules, you are receiving this notice that the proxy materials for LivaNova PLC’s 2026 Annual General Meeting ("AGM") are available on the Internet. Follow the instructions below to view the materials and vote online or request a copy. The items to be voted on and location of the annual meeting are on the reverse side. Your vote is important! This communication presents only an overview of the more complete proxy materials that are available to you on the internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The Notice of Meeting, 2026 Proxy Statement, 2025 U.S. Annual Report on Form 10-K, and 2025 UK Annual Report are at: Obtaining a Copy of the Proxy Materials – If you want to receive a copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. Please make your request as instructed on the reverse side on or before May 30, 2026 to facilitate timely delivery. 2NOT Easy Online Access — View your proxy materials and vote. When you go online, you can also help the environment by consenting to receive electronic delivery of future materials. Step 4: Make your selections as instructed on each screen for your delivery preferences. Step 5: Vote your shares. Votes submitted online or by phone must be received by 3:00 pm British Summer Time, on June 10, 2026 MMMMMMMMMMMM MMMMMMMMM 000001MR A SAMPLE DESIGNATION (IF ANY) ADD 1 ADD 2 ADD 3 ADD 4 ADD 5 ADD 6 ENDORSEMENT_LINE______________ SACKPACK_____________ 1234 5678 9012 345 C 1234567890 COY MMMMMMM

    GRAPHIC

    Here’s how to order a copy of the proxy materials and select delivery preferences: Current and future delivery requests can be submitted using the options below. If you request an email copy, you will receive an email with a link to the current meeting materials. PLEASE NOTE: You must use the number in the shaded bar on the reverse side when requesting a copy of the proxy materials. — Internet – Go to www.envisionreports.com/LIVN. Click Cast Your Vote or Request Materials. — Phone – Call us free of charge at 1-866-641-4276. — Email – Send an email to envisionreports@computershare.com with "Proxy Materials LivaNova PLC" in the subject line. Include your full name and address, plus the number located in the shaded bar on the reverse side, and state that you want a paper copy of the meeting materials. To facilitate timely delivery, all requests for a paper copy of proxy materials must be received by May 30, 2026. The LivaNova PLC 2026 Annual General Meeting will be held on June 10, 2026 at 3:00 pm British Summer Time/10:00 am Eastern Time, virtually at meetnow.global/MM4W4G7. The Board of Directors recommends a vote FOR all the nominees and FOR Proposals 2-10. 1. Ordinary Resolution: To elect, by separate resolution, each of the following eleven (11) directors for a term expiring at the AGM to be held in 2027 ("2027 AGM"): 01 J. Christopher Barry 02 Francesco Bianchi 03 Stacy Enxing Seng 04 William Kozy 05 Vladimir Makatsaria 06 Jette Nygaard-Andersen 07 Susan Podlogar 08 Todd Schermerhorn 09 Brooke Story 10 Peter Wilver 11 Donald Zurbay 2. Ordinary Resolution: To approve, on an advisory basis, the Company’s compensation of its named executive officers ("U.S. Say on Pay"). 3. Ordinary Resolution: To ratify the appointment of PricewaterhouseCoopers LLP, a Delaware limited liability partnership ("PwC-US"), as the Company’s independent registered public accounting firm for 2026. 4. Ordinary Resolution: To generally and unconditionally authorize the directors, for the purposes of section 551 of the Companies Act 2006 (the “Companies Act”), to exercise all powers of the Company to allot shares in the Company and to grant rights to subscribe for, or to convert any security into, shares in the Company up to an aggregate nominal amount of £10,985,296, provided that: (A) (unless previously revoked, varied, or renewed by the Company) this authority will expire at the end of the next annual general meeting of the Company or, if earlier, the close of business on the date that is fifteen (15) months after the date on which this resolution is passed, save that the directors may, before this authority expires, make offers or agreements which would or might require shares in the Company to be allotted, or rights to subscribe for, or convert securities into, shares to be granted, after its expiry and the directors may allot shares or grant rights to subscribe for, or convert securities into, shares pursuant to such offers or agreements as if this authority had not expired; and (B) this authority replaces all subsisting authorities previously granted to the directors for the purposes of section 551 of the Companies Act which, to the extent unused at the date of this resolution, are revoked with immediate effect without prejudice to any allotment of shares or grant of rights already made, offered, or agreed to be made under such authorities. 5. Special Resolution: Subject to the passing of resolution 4 and in accordance with sections 570 and 573 of the Companies Act, to empower the directors generally to allot equity securities (as defined in section 560 of the Companies Act) for cash pursuant to the authority conferred by resolution 4, and/or to sell Ordinary Shares (as defined in section 560 of the Companies Act) held by the Company as treasury shares for cash, in each case as if section 561 of the Companies Act (existing shareholders’ pre-emption rights) did not apply to any such allotment or sale, provided that this power is limited to the allotment of equity securities or sale of treasury shares for cash up to an aggregate nominal amount of £10,985,296, provided that: (A) (unless previously revoked, varied, or renewed by the Company) this power will expire at the end of the next annual general meeting of the Company or, if earlier, the close of business on the date that is fifteen (15) months after the date on which this resolution is passed, save that the directors may, before this power expires, make offers or agreements which would or might require equity securities to be allotted and/or treasury shares to be sold after its expiry and the directors may allot equity securities and/or sell treasury shares pursuant to such offers or agreement as if this power had not expired; and (B) this power replaces (except for any power conferred by resolution 4) all subsisting powers previously granted to the directors for the purposes of section 570 of the Companies Act which, to the extent unused at the date of this resolution, are revoked with immediate effect, without prejudice to any allotment of equity securities already made, offered, or agreed to be made under such powers 6. Ordinary Resolution: To approve, for the purposes of section 694 of the Companies Act, the terms of the proposed share repurchase contracts set out in Appendix A and Appendix B of this proxy statement (the “Share Repurchase Contracts”) and to authorize the Company to enter into a Share Repurchase Contract with any of the Approved Counterparties (as defined in this proxy statement) provided that: (A) the maximum aggregate number of Ordinary Shares that may be purchased pursuant to the Share Repurchase Contracts shall not exceed 10% of the total issued Ordinary Shares of the Company as at 5:00 pm Eastern Time on April 13, 2026 as adjusted on a proportionate basis to take into account any consolidation or division of shares from time to time; and (B) (unless previously revoked, varied, or renewed by the Company) this authority will expire at the end of the next annual general meeting of the Company or, if earlier, the date that is fifteen (15) months after the date on which this resolution is passed, save that the Company may enter into any Share Repurchase Contract with any of the Approved Counterparties under this authority prior to its expiry and may purchase Ordinary Shares pursuant to any such Share Repurchase Contract. 7. Ordinary Resolution: To approve, on an advisory basis, the United Kingdom (“UK”) directors’ remuneration report in the form set out in the Company’s UK annual report (the “UK Annual Report”) for the year ended December 31, 2025. 8. Ordinary Resolution: To receive and adopt the Company’s audited UK statutory accounts for the year ended December 31, 2025, together with the reports of the directors and auditors thereon. 9. Ordinary Resolution: To re-appoint PricewaterhouseCoopers LLP, a limited liability partnership organized under the laws of England (“PwC-UK”), as the Company’s UK statutory auditor for 2026. 10. Ordinary Resolution: To authorize the directors and/or the Audit and Compliance Committee to determine the remuneration of the Company’s UK statutory auditor. PLEASE NOTE – YOU CANNOT VOTE BY RETURNING THIS NOTICE. To vote your shares, you must go online or request a paper copy of the proxy materials to receive a proxy card. In order to attend the virtual 2026 Annual General Meeting, please follow the instructions set forth in the proxy statement. 2026 Annual General Meeting Notice

    Get the next $LIVN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LIVN

    DatePrice TargetRatingAnalyst
    12/19/2025$81.00Overweight
    KeyBanc Capital Markets
    10/1/2025$55.00Buy → Neutral
    Goldman
    5/20/2025$60.00Peer Perform → Outperform
    Wolfe Research
    2/26/2025Outperform → Peer Perform
    Wolfe Research
    10/4/2024$65.00Buy
    Goldman
    9/17/2024$55.00 → $66.00Neutral → Outperform
    Robert W. Baird
    3/20/2024Buy
    Needham
    2/20/2024$60.00 → $70.00Neutral → Buy
    Mizuho
    More analyst ratings

    $LIVN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bianchi Francesco sold $136,350 worth of Ordinary Shares (1,800 units at $75.75), decreasing direct ownership by 20% to 7,228 units (SEC Form 4)

    4 - LivaNova PLC (0001639691) (Issuer)

    5/27/26 4:51:27 PM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Tezel Ahmet

    4 - LivaNova PLC (0001639691) (Issuer)

    4/1/26 5:20:30 PM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Poletti Franco

    4 - LivaNova PLC (0001639691) (Issuer)

    4/1/26 5:20:24 PM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $LIVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    KeyBanc Capital Markets initiated coverage on LivaNova with a new price target

    KeyBanc Capital Markets initiated coverage of LivaNova with a rating of Overweight and set a new price target of $81.00

    12/19/25 8:50:10 AM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    LivaNova downgraded by Goldman with a new price target

    Goldman downgraded LivaNova from Buy to Neutral and set a new price target of $55.00

    10/1/25 8:42:07 AM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    LivaNova upgraded by Wolfe Research with a new price target

    Wolfe Research upgraded LivaNova from Peer Perform to Outperform and set a new price target of $60.00

    5/20/25 8:01:26 AM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $LIVN
    SEC Filings

    View All

    SEC Form SD filed by LivaNova PLC

    SD - LivaNova PLC (0001639691) (Filer)

    5/29/26 4:13:09 PM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form IRANNOTICE filed by LivaNova PLC

    IRANNOTICE - LivaNova PLC (0001639691) (Filer)

    5/6/26 1:03:33 PM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 10-Q filed by LivaNova PLC

    10-Q - LivaNova PLC (0001639691) (Filer)

    5/6/26 1:01:33 PM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $LIVN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    LivaNova Appoints Stefano Folli to Lead its Cardiopulmonary Business Unit

    LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that Stefano Folli will join the Company as incoming President, Cardiopulmonary (CP), effective June 1, succeeding Franco Poletti, who will retire on July 31. Folli will partner closely with Poletti over the coming months to ensure a seamless leadership transition before assuming full responsibility for the business on August 1. Folli will join the LivaNova Executive Leadership Team and report to Chief Executive Officer Vladimir Makatsaria. "Stefano is an accomplished healthcare and medtech executive with a sharp blend of strategic vision and operational excellence," Makatsaria said. "With more than t

    5/21/26 9:15:00 AM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    LivaNova to Present at Goldman Sachs Global Healthcare Conference in June

    LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced it will present at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami Beach, Fla. Vladimir Makatsaria, Chief Executive Officer of LivaNova; Alex Shvartsburg, Chief Financial Officer; and Phil Kowalczyk, Chief Strategy and Corporate Development Officer, will participate in a fireside chat on Mon., June 8, 2026, at 8 a.m. Eastern Daylight Time. The discussion will be available to all interested parties who register to attend the webcast, which is accessible via www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup of the webcast. A r

    5/19/26 8:00:00 AM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    LivaNova Reports First-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance

    – Delivered double-digit reported and constant-currency revenue growth – Raised full-year 2026 revenue and adjusted diluted earnings per share guidance(1) – Received U.S. Food and Drug Administration premarket approval for aura6000 System to treat moderate to severe obstructive sleep apnea LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today reported results for the first quarter ended March 31, 2026 and raised full-year 2026 guidance. Financial Summary and Highlights(1) First-quarter revenue of $362.3 million increased 14.3% on a reported basis and 11.1% on a constant-currency basis as compared to the prior-year period First-quarter U.S. GAAP diluted

    5/6/26 6:00:00 AM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $LIVN
    Leadership Updates

    Live Leadership Updates

    View All

    LivaNova Appoints Stefano Folli to Lead its Cardiopulmonary Business Unit

    LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that Stefano Folli will join the Company as incoming President, Cardiopulmonary (CP), effective June 1, succeeding Franco Poletti, who will retire on July 31. Folli will partner closely with Poletti over the coming months to ensure a seamless leadership transition before assuming full responsibility for the business on August 1. Folli will join the LivaNova Executive Leadership Team and report to Chief Executive Officer Vladimir Makatsaria. "Stefano is an accomplished healthcare and medtech executive with a sharp blend of strategic vision and operational excellence," Makatsaria said. "With more than t

    5/21/26 9:15:00 AM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    LivaNova Appoints Lucile Blaise as Global Head of Commercialization, Obstructive Sleep Apnea

    LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, announced Lucile Blaise has joined the Company as Global Head of Commercialization, Obstructive Sleep Apnea (OSA), effective December 1. Blaise reports to Vladimir Makatsaria, Chief Executive Officer and is a member of the Executive Leadership Team. "Lucile is an accomplished healthcare executive with more than 25 years of leadership in the medtech sector," Makatsaria said. "With her extensive OSA market expertise, she has a strong track record in creating new sleep therapy pathways, improving patient access to care, and building strong commercial teams. Her leadership will help us unlock transformational growth by co

    12/2/25 9:00:00 AM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    LivaNova Appoints Donald Zurbay as a New Director

    LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, announced the appointment of Donald (Don) Zurbay to the Company's Board of Directors, effective today. Zurbay will serve on the Audit and Compliance Committee for the Board. "LivaNova is pleased to welcome Don to our Board of Directors," said William Kozy, Chair of the Board. "Over the course of 30 years, he has amassed expertise in finance, accounting, and strategy, much of which he honed while serving in leadership positions with global healthcare companies. His deep experience and knowledge will be welcome assets to the Board." Zurbay joins the LivaNova Board of Directors after a seven-year tenure at Patterson C

    9/4/25 9:00:00 AM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $LIVN
    Financials

    Live finance-specific insights

    View All

    LivaNova Reports First-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance

    – Delivered double-digit reported and constant-currency revenue growth – Raised full-year 2026 revenue and adjusted diluted earnings per share guidance(1) – Received U.S. Food and Drug Administration premarket approval for aura6000 System to treat moderate to severe obstructive sleep apnea LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today reported results for the first quarter ended March 31, 2026 and raised full-year 2026 guidance. Financial Summary and Highlights(1) First-quarter revenue of $362.3 million increased 14.3% on a reported basis and 11.1% on a constant-currency basis as compared to the prior-year period First-quarter U.S. GAAP diluted

    5/6/26 6:00:00 AM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    LivaNova to Announce First-Quarter 2026 Results

    LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, will host a conference call to discuss its first-quarter 2026 results on Wed., May 6, 2026, at 1 p.m. London time (8 a.m. Eastern Daylight Time). The Company will release its first-quarter 2026 results prior to the call. The audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. To listen to the conference call by telephone, dial +1 833 470 1428 (if dialing from within the U.S.) or +1 929 526 1599 (if dialing from outside the U.S.). The conference call access code is 946097. A replay will be available on the

    3/25/26 9:00:00 AM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    LivaNova Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Guidance

    – Delivered double-digit reported and organic revenue growth and continued operating margin expansion for full-year 2025 – Issued full-year 2026 guidance, including constant-currency revenue growth between 6.0% and 7.0% and adjusted diluted earnings per share in the range of $4.15 to $4.25 – Received increased provider reimbursement from U.S. Centers for Medicare & Medicaid Services for VNS Therapy for Drug-Resistant Epilepsy procedures, effective Jan. 1, 2026, significantly reducing a known barrier to procedure penetration – Received U.S. Food and Drug Administration approval for cloud-based digital health platform LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology com

    2/25/26 6:00:00 AM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $LIVN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by LivaNova PLC

    SC 13G - LivaNova PLC (0001639691) (Subject)

    4/17/24 4:19:05 PM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by LivaNova PLC (Amendment)

    SC 13G/A - LivaNova PLC (0001639691) (Subject)

    2/12/24 4:01:13 PM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by LivaNova PLC (Amendment)

    SC 13G/A - LivaNova PLC (0001639691) (Subject)

    1/23/24 11:52:27 AM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care